Brilliant Blue G
| 规格 | 价格 | 货期 | 数量 |
|---|---|---|---|
| 100g | ¥791.00 | 现货 |
特色产品
- 用于免疫印迹和质谱分析等后续操作
- 适用于30 KDa-130 KDa大小的蛋白
- 可将信号灵敏度提高100倍
- 同时保持稳定的特异性和分辨率
- 提供更高的转录效率并抑制免疫激活
- 使用5-moUTP和Cy5-utp修饰
产品描述
Brilliant Blue G is also a selective inhibitor of the P2X purinoceptor channel P2X7 [1].
P2X receptors are membrane ion channels activated in response to the binding of extracellular ATP. Seven P2X subtypes have been identified. P2X receptors have been involved in in diverse patho- and physiological processes, such as the autonomic nervous system, afferent signalling, chronic pain, and in autocrine loops of endothelial and epithelial cells. The P2X7 receptor plays a prominent role in certain neurologic disorders, such as ischemia-reperfusion injury, Alzheimer's disease, spinal cord injury and sensory neuropathies [2].
In HEK293 cells heterologously expressing human P2X7 receptors, Brilliant Blue G noncompetitively inhibited rat and human P2X7 receptors with IC50 values of 10 and 200 nM, respectively. The IC50 values for inhibition of the other P2X receptors ranged from 2 to >30 μM; Brilliant Blue G inhibited the rat and human P2X4 receptors with the IC50 values of >10 and 3.2 μM [1]. Subretinal injection of BBG caused retinal cell degeneration at lower concentrations. Subretinal injection of BBG (0.25 mg/mL) provided satisfactory biocompatibility [3].
References:
[1] Jiang L H, Mackenzie A B, North R A, et al. Brilliant blue G selectively blocks ATP-gated rat P2X7 receptors[J]. Molecular pharmacology, 2000, 58(1): 82-88.
[2] Sperlágh B, Vizi E S, Wirkner K, et al. P2X 7 receptors in the nervous system[J]. Progress in neurobiology, 2006, 78(6): 327-346.
[3] Ueno A, Hisatomi T, Enaida H, et al. Biocompatibility of brilliant blue G in a rat model of subretinal injection[J]. Retina, 2007, 27(4): 499-504.
产品性质
| 物理外观 | Solid |
| CAS号 | 6104-58-1 |
| 分子式 | C47H48N3O7S2·Na |
| 分子量 | 854 |
| 小分子别名 | Brilliant blue G-250 |
| 化学名称 | N-[4-[[4-[(4-ethoxyphenyl)amino]phenyl][4-[ethyl[(3-sulfophenyl)methyl]amino]-2-methylphenyl]methylene]-3-methyl-2,5-cyclohexadien-1-ylidene]-N-ethyl-3-sulfo-benzenemethanaminium, sodium salt |
| 溶解度 | ≥21.35 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH |
| SMILES | CC1=CC(N(CC)CC2=CC=CC(S(=O)([O-])=O)=C2)=CC=C1/C(C3=CC=C(NC4=CC=C(OCC)C=C4)C=C3)=C5C=C/C(C=C\5C)=[N+](CC6=CC=CC(S(=O)([O-])=O)=C6)/CC.[Na+] |
| 存储条件 | 室温 |
| 运输条件 | 蓝冰 |
产品应用 (实验数据来自文献,APExBIO并未验证,仅供参考)
IC50和靶点
| 生物活性描述 | 亮蓝 G 是 P2X7 嘌呤能受体的拮抗剂。 |
| 靶点 | P2X purinergic receptor |



沪公网安备 31011002003500